Placenta DiseasesNCT03731949
Placental Volume Analysis During Pregnanay
An observational study of Placenta Diseases, run by Aljazeera Hospital at 1 site in Egypt.
Trial summary
Placenta grows with advancing gestational age amonitoring of placental growth is important in pregnancy evaluation Read more about this study
- Who is it for?
- Ages 20 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Placenta Diseases
- What is being tested?
- Ultrasonography
- How many people
- 500 participants
- Where
- 1 siteEgypt
- Study dates
- 16 Nov 2018to 5 Jul 2019
- How long will I take part?
- 4 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: * pregnant ladies between 20 - 40 years old * ladies pregnant from 14 weeks till term
Who may be able to join
- pregnant ladies between 20 - 40 years old
- ladies pregnant from 14 weeks till term
Who cannot join
- pregnant ladies in first trimester
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Algazeerah and Kasralainy hospital
Giza
Mahmoud Alalfy, master, +201002611058, mahmoudalalfy@ymail.com
Ahmed Elgazzar, M.D, +201014005959
About this study
Official title: Placental Volume Analysis and Monitoring and Vascularity Assessment
Placenta grows with advancing gestational age amonitoring of placental growth is important in pregnancy evaluation
Read the detailed description
assessment of placental size is very important in evaluating the pregnancy Placenta is one of the most important organs that control pregnancy outcome
- Conditions
- Placenta Diseases
- Being tested
- Ultrasonography
- Medical subject headings
- Placenta Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
UltrasonographyDiagnostic test
Ultrasonography to assess placental volume
What is being measured
The primary outcome is the main question the study is designed to answer.
the volume of every placenta at the given time of scan
volume of placenta that will increase with time
Measured: within 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2018
- Study start16 Nov 2018
- Primary completion1 Jun 2019 (estimated)
- Study completion5 Jul 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Placenta DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 4 Months
Sponsor and investigators
- Lead sponsor
- Aljazeera Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Kasr El Aini Hospital, National Research Centre, Egypt
- Responsible party
- Principal investigator, Mahmoud Alalfy, Aljazeera Hospital
- Investigators
- Mahmoud Alalfy, Principal investigator, Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03731949
- Sponsor's protocol ID
- placental growth
- Status last verified
- Jan 2019
- First submitted
- 4 Nov 2018
- Last updated
- 10 Jan 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Placental Volume Analysis and Monitoring and Vascularity Assessment
- ClinicalTrials.gov ID
- NCT03731949
- Acronym / sponsor ID
- placental growth
- Conditions
- Placenta Diseases
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Aljazeera HospitalUniversity, hospital or other
- Collaborators
- Kasr El Aini Hospital, National Research Centre, Egypt
- Study start
- 16 Nov 2018 (actual)
- Primary completion
- 1 Jun 2019 (estimated)
- Study completion
- 5 Jul 2019 (estimated)
- First posted
- 6 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Placenta grows with advancing gestational age amonitoring of placental growth is important in pregnancy evaluation
Detailed description
assessment of placental size is very important in evaluating the pregnancy Placenta is one of the most important organs that control pregnancy outcome
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 4 Months
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- * pregnant ladies between 20 - 40 years old * ladies pregnant from 14 weeks till term
Key inclusion criteria (2 listed)
- pregnant ladies between 20 - 40 years old
- ladies pregnant from 14 weeks till term
Key exclusion criteria (1 listed)
- pregnant ladies in first trimester
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| UltrasonographyUltrasonography to assess placental volume | Diagnostic test | – |
Primary outcome
the volume of every placenta at the given time of scan
Time frame: within 2 months
volume of placenta that will increase with time
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jan 2019.
Related trials for Placenta Diseases
RecruitingObservational study
Effects of Tuberculosis Infection on Development and Function of the Placenta
Pregnancy Related, Tuberculosis Infection
RecruitingObservational study
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
High Risk Pregnancy, Congenital Heart Disease
Recruiting
Characterization of Placental Diffusion
Pregnancy in Diabetic, Placenta Diseases
RecruitingObservational study
Twin Pregnancy: a Challenge for Patients, Families and Health Professionals
Twin Pregnancy With Antenatal Problem, Twin Diseases
RecruitingObservational study
Diagnosis and Outcomes of Placental Accretism
Placenta Accreta
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mahmoud Alalfy principal investigator
Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Placenta Diseases, run by Aljazeera Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mahmoud Alalfy (01002611058, mahmoudalalfy@ymail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the volume of every placenta at the given time of scan (time frame: within 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2019; AzTrials last refreshed its copy on 2 Nov 2026.